Clinical trial
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer…
NCT00004001 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00004001 |
|---|---|
| Title | S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B North Central Cancer Treatment Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, estramustine, mitoxantrone, prednisone |
| Enrollment | 770 |
| Start date | Oct 1, 1999 |
| Primary completion | Jul 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 25, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: